Integumen PLC (LON:SKIN) shares rose on Thursday as the cosmetics testing group said it has added two industry veterans to its senior management team.
Paul Ryan has been appointed as the company’s head of enterprise sales at Labskin AI – the digital extension to Integumen’s lab-grown skin which helps cut the cost of the testing process in half.
READ: Integumen seeing commercial traction for Labskin AI testing product
Ryan has previously managed strategic partnering programmes with companies such as Siemens, Microsoft and IBM. He joins from 8 West CONsulting where he was head of business development, working with clients including Avon and Estee Lauder.
Integumen has also brought in Colin O’Sullivan as its chief information officer, a position he previously held at the Australian Medical Association.
Integumen said O’Sullivan brings extensive cross-platform software experience in medical and science applications ranging from enterprise applications, cloud computing, artificial intelligence, IT operations, customer experience and development operations.
During his six-year stint at the AMA, he was responsible for “transforming” the group’s online business.
New guys will help drive growth
“We are delighted and fortunate to add these two exceptional individuals to the Integumen team,” said chief executive Gerard Brandon.
“Under Paul's guidance, the sales team will advance the growth of Labskin AI by leveraging the existing sales, marketing and distribution channels of the Labskin laboratory services.”
He added: “Colin's Australian continent AI and IT operational expertise ensures Labskin AI has an architect capable of building out continent-wide bases to deliver a robust global infrastructure.”
New offices and warrant exercise
In the same statement, Integumen confirmed it has moved into its new “state-of-the-art” offices in Cork, Ireland following the recent acquisition of RinoCloud.
CEO Brandon said: “Our new offices in Cork, Ireland, bring the core digital and enterprise sales teams together and are located close to many US and EU pharmaceutical corporations that fit our client target profiles. This expansion adds another exciting new chapter for Integumen.”
In a separate stock exchange announcement, the AIM-quoted company confirmed a shareholder had exercised warrants over 2.5mln shares, bringing in £37,500.
In afternoon trading, shares in Integumen were 5.2% higher at 2.43p.
-- Adds share price --